TPE24 | Interview with U.S. Congressional Candidate: "What FDA are Doing is Criminal Because They're Killing American Citizens"

Industry Insight by 2FIRSTS, edited by Sophia
Feb.02.2024
TPE24 | Interview with U.S. Congressional Candidate: "What FDA are Doing is Criminal Because They're Killing American Citizens"
U.S. political commentator Drew Johnson is calling for a reform of FDA policies, advocating for e-cigarettes as a life-saving method. He points out that the government and pharmaceutical companies are attempting to hinder the development of e-cigarettes, emphasizing that e-cigarettes are a relatively inexpensive and convenient option. Johnson sharply criticized FDA regulations, stating that they restrict the e-cigarette industry.

On February 1st, 2FIRSTS engaged in a discussion with Drew Johnson, a U.S. political commentator and congressional candidate, at the TPE24 trade show. Johnson advocated for FDA policy reform, supporting electronic cigarettes as a life-saving method. He pointed out that the government and pharmaceutical companies are attempting to impede the development of e-cigarettes, emphasizing that they are a relatively inexpensive and convenient choice.

 

Simultaneously, Johnson expressed disappointment over the UK's ban on disposable e-cigarettes, believing it would deprive some people of convenience. He sharply criticized FDA regulations, stating that they limit the e-cigarette industry. If elected, he pledged to support policies that contribute to longer and healthier lives.

 

The following is a summary of the Q&A session:

 

Q: Let me begin with my first question. My first question is just asked by David just now. What brings your here?

 

Vaping has actually been an interest of mine for a while, because I saw working in public policy that vaping is the best way for people to stop smoking.

 

It saves lives. It's relatively cheap and convenient and I get really frustrated when I see governments try to ban vaping, try to to regulate it out of existence and try to push it on a black market, because ultimately vaping saves lives and anything we as a government can do is to promote vaping over smoking.

 

And also I've seen some some real problems with Big Tobacco and also Pharm try to kill vaping because they obviously have products that compete with vaping so you see things like pharm, they've got their patches and the gums and things that aren't as effective as vaping, but they want to make sure those products are still being sold, so they actually lobby against vaping.

 

I've seen this a lot on the international level through the whole and also here in the States where pharmaceutical companies basically lobby and try to get government to be persuaded by lying about some of the dangers with it.

 

Q: So that's why this TPE show is like, as you posted, most of the vapes are illegal, but that is something that saves people's lives. How do you like this TPE show?

 

It's been incredible to see the technology, to see the harm reduction efforts, to see all the options that are available. Really it's my goal to get the word out that there are these things available and that you know I don't have a problem with government regulating and making them as safe as possible.

 

We just need to get them to the market so the more we can get these products on the market safely, effectively, efficiently, so that people have adults who smoke have the opportunity to decide whether they want to vape instead, the better off we all are.

 

Q: That's good to know. Actually just before the TPE begins, we just heard a news from the UK that Rishi Sunak, the PM of UK, just announced to ban the disposable vapes in the UK. What do you think of this policy? Do we have something to learn from, or take a reference from, or take a leaf from?

 

First of all, it's really disappointed to hear UK is going in this direction because for years the UK has really been a model for the United States because the government of the UK admits that vaping is healthier than smoking and actually provides baits to people to help them stop smoking.

 

The problem with this decision to ban disposable vapes is that the people who tend to use disposable vapes are older people with disabilities. Things like that make it hard for them to use the big tanks and the liquids things so it takes away the most convenient, easiest way for people to vape.

 

And I think unfortunately, I think in the UK you want to see more people decide to stick with smoking because they don't have that option of the easiest way to vaping. It's a terrible decision.

 

Q: We also have noticed that the FDA has been unsatisfactory, especially this is a quote from the ex-FDA official the day before yesterday at the educational session. What do you think of the FDA's regulation and their enforcement?

 

The FDA what they're doing is criminal because they're killing American citizens. The FDA tries to act like they want to allow vaping but ultimately the regulations can use change every time a new company tries to put something on the market and so there's no consistency.

 

There's a clear motivation by the FDA was sort of help captive by Big Pharma and Big Tobacco to push out the vape industry and it's it's really concerning. I think that obviously there needs to be some regulation. There needs to be accountability in the industry but at the end of the day what's gonna help people stop smoking is vaping.

 

We see that vaping is the most effective way to help people stop smoking so when the FDA gets in the way that ultimately they are killing Americans and we can't have a government agency killing Americans through the bad policy.

 

Q: In a previous research from 2FIRSTS, we notice that there's a kind of a very distinguished difference between the blue states and red states which is governed by Republicans and Democrats so we see a difference between them. Attitudes towards vape in the republican states or red states, embracing the vaping industry and the Democrats states this is doing the opposite.

 

Q: For example like all the flavor bans happening, why do you think this scenario is happening? What's the reason?

 

More Republicans tend to believe that people can make better decisions for themselves than government they want to have more individual liberties let people make decisions for themselves and part of that is deciding whether to vape or smoke.

 

I do appreciate that there are a lot of Republican governors and Republican state lawmakers in these red states who are empowering people to have the option. In these democratic moblue states you're seeing flavor bans. I think every flavor ban in America has has come from a democratic city or in a state and ultimately when you get rid of flavors and and options you encourage people to smoke because people usually like the way smoking tastes, the way it makes them feel, and there needs to be a realistic option for them to transition to.

 

It concerns me that Democrats by micromanaging people's lives and people are actually doing a lot more harm than good because if they just embrace vaping is an option for adults if they regulated. It made sure as the red says are doing that you know people under 18 or 21 don't vape. I think it would solve a lot of problems when it comes to health and helping people to stop smoking.

 

Q: Empowering people to have more options and another question this question is kind of like an ambitious one. So should you be the congressman, what policies would you like to propose or adopt?

 

Absolutely. So if I'm fortunate enough to be elected, what I would like to see is the FDA treat vaping completely differently I would like the process that the FDA uses to bring new vape products into the market easier. so this policy of basically making vape illegal, where vaping has to exist on the black market and that's my number one concern the other issue is flavor bans which we see on the state level and the local level right now I know some members of Congress want to have flavor bans nationaly and that's just not a realistic option if the goal is to help people stop smoking. So at the end of the day I am for anything that helps people live longer lives live healthier lives.

 

I'm for adults being able to make decisions about their own lives and they choose to date and that's fine but but ultimately anything I can do to to save lives through helping people stop smoking. I think that's something that could be well and colleges and those sorts of policies what are what I'm gonna advocate one of my life.

 

Q: That's a terrific prospect to me actually it's very great and because there are still a very huge base of readers from China so can you also make like an ABC knowledge for the Chinese readers to, like enforcement and legislation on the FDA level and on the Nevada state level? So state level and FDA federal level.

 

Basically the way it works in America right now is the FDA has more or less banned vaping so it's very difficult in the United States to go through the process to legally bring vape products to market. There are some loopholes in some ways that you can pay hundreds of millions of dollars to bring products to market ultimately most vape products are banned now.

 

The way that people get around this is they sell them legally through the black market from other convenience stores or maybe a marijuana glass store and so they're still being based on it sold gratefully, but that's kind of where the state of Nevada comes in. we don't right now have flavor bans we don't have.

 

Here's a lot of regulations that you see in California, Connecticut, New York City, like that Portland but my goal my hope is that the FDA makes it easier for vape products to be above ground to sell legally to regulate them make sure that they're safe and that the products inside them are safe and less harmful and the more that we can do that the better off we are both in terms of health care cost terms of saving lives and encouraging people with longer healthier lives and helping people stop smoking.

 

I think that's all of our questions. thank you, thank you for joining us.

 

Absolutely thank you for having me.

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane’s 2026 update of its living review on electronic cigarettes for smoking cessation included 80 randomized controlled trials involving 29,861 adult smokers, with nine trials added in this update. The review retained its high-certainty conclusion that nicotine e-cigarettes increase smoking cessation rates compared with nicotine replacement therapy. In absolute terms, about 10 in 100 people using nicotine e-cigarettes may quit smoking for at least six months, compared with about 6 in 100 using NRT. The review found no clear difference in serious adverse event rates between the two groups, while longer-term safety and the relative effectiveness of newer device types remain less certain.
Sep.07
FDA Unifies Tobacco Registration and Product Listing Form Across Product Categories
FDA Unifies Tobacco Registration and Product Listing Form Across Product Categories
The U.S. FDA has consolidated two tobacco establishment registration and product listing forms into a redesigned Form FDA 3741 covering all regulated product categories, including e-cigarettes, heated tobacco products and nicotine pouches. The current requirements remain limited to domestic establishments. Separately, the FDA has proposed extending registration and product listing requirements to foreign manufacturers, signaling greater regulatory attention to manufacturing entities and product-level information across the tobacco and nicotine supply chain.
FDA
Sep.30
Imperial Brands Sees Double-Digit NGP Growth as Sixth Year of Tobacco Revenue Gains Backs £1.5 Billion Buyback
Imperial Brands Sees Double-Digit NGP Growth as Sixth Year of Tobacco Revenue Gains Backs £1.5 Billion Buyback
Imperial Brands reaffirmed its FY26 guidance in its October 8 pre-close trading update, forecasting double-digit net revenue growth in next-generation products and share gains across heated tobacco, vape and modern oral. Tobacco net revenue is expected to grow at a low-single-digit rate, marking a sixth consecutive year of growth. The company has completed its £1.45 billion FY26 share repurchase and announced a £1.5 billion buyback for FY27. Group adjusted operating profit is expected to increase 3% to 5%, while free cash flow is forecast to exceed £2.2 billion.
Oct.09
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
FDA’s Center for Tobacco Products is reshaping how it approaches tobacco product review. Based on 2Firsts’ on-site reporting in New York and Washington, this report traces CTP’s emerging direction: stronger links between PMTA and tobacco harm reduction, more category-specific review, greater emphasis on decision-relevant science, more predictable timelines and expanded use of sPMTA for product modifications. CTP also acknowledged major constraints, including just nine PMTA review teams, persistent backlogs and limits on hiring capacity.
Regulations
Oct.08
As Regulators Focus on Nicotine Pouch Child Safety, Safeguard Pursues an External Packaging Route
As Regulators Focus on Nicotine Pouch Child Safety, Safeguard Pursues an External Packaging Route
As regulators pay closer attention to child safety in nicotine pouches, manufacturers face a practical challenge: how to strengthen child-resistant packaging without unnecessarily reworking products, production lines and regulatory submissions already in place. In a written interview with 2Firsts, Chemular detailed Safeguard’s external packaging approach, its customer-specific testing requirements and possible PMTA pathways. The model remains early-stage, but it offers a new way to think about an increasingly important regulatory and manufacturing issue.
Industry Insight
Sep.19
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
A commentary published in the international open-access, peer-reviewed Harm Reduction Journal argues that randomized controlled trials remain central to evaluating smoking cessation efficacy but cannot alone capture real-world uptake, complete switching, longer-term use and population impact of non-combustible nicotine products such as e-cigarettes, heated tobacco and nicotine pouches. The authors frame impact as “reach × efficacy” and call for real-world evidence to complement RCTs. Three days after publication, the FDA authorized three JUUL2 products and highlighted complete switching among adult smokers in explaining its decision, providing a timely regulatory backdrop to the debate.
Sep.08